Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic - 19/06/20
Doi : 10.1016/j.jaad.2020.04.143
Daniela P. Sanchez, BS a, b, Robert S. Kirsner, MD, PhD a, Hadar Lev-Tov, MD a, ⁎ 
a Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida
b Boston University School of Medicine, Boston, Massachusetts
∗Correspondence to: Hadar Lev-Tov, MD, University of Miami Miller School of Medicine, 1600 NW 10th Ave, RMSB 2023A, Miami, FL 33136University of Miami Miller School of Medicine1600 NW 10th AveRMSB 2023AMiamiFL33136
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 1
P. 288-292 - juillet 2020 Retour au numéro
Article précédent
- Recommendations for phototherapy during the COVID-19 pandemic
- Henry W. Lim, Steven R. Feldman, Abby S. Van Voorhees, Joel M. Gelfand
- COVID-19 and biologics for psoriasis: A high-epidemic area experience—Bergamo, Lombardy, Italy
- Andrea Carugno, Daniele Mario Gambini, Francesca Raponi, Pamela Vezzoli, Andrea Gustavo C. Locatelli, Marco Di Mercurio, Elisa Robustelli Test, Paolo Sena
Bienvenue sur EM-consulte, la référence des professionnels de santé.